




The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 303%, being 40% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	9,647
Cost of Goods Sold	6,566
Intangible Assets	0
Liabilities, Current	2,581
Liabilities, Non-Current	0
Other Assets	4,606
Other Compr. Net Income	0
Other Expenses	59
Other Liabilities	413
Other Net Income	-1,485
Other Revenues	13,854
Property and Equipment	795
Research and Development	1,533
Selling, General and Administrative Expense	12,414

Output Variable	Value in 1000 USD
Assets	15,048
Liabilities	2,994
Expenses	20,572
Revenues	13,854
Stockholders Equity	12,054
Net Income	-8,203
Comprehensive Net Income	-8,203
BaseVar	26,976
ECR before Limited Liability	200%
Economic Capital Ratio	303%